What is the global market size of the Hereditary Angioedema Treatment Market?

Global Hereditary Angioedema Treatment Market size was valued at USD 2.65 billion in 2021 and is poised to grow from USD 2.72 billion in 2022 to USD 10.39 billion by 2030, growing at a CAGR of 2.56% in the forecast period (2023-2030).

Hereditary Angioedema Treatment Market Size, Share, Growth Analysis, By Drug class(C1-esterase inhibitor, Brandykinin B2 receptor antagonist, Kallikrein inhibitor, others), By Treatment(Prophylaxis, On-demand), By Route of administration(Intravenous, Subcutaneous, Oral), By Distribution channel(Hospital pharmacy, Retail Pharmacy), By Application(Prophylaxis and Treatment), By Region - Industry Forecast 2024-2031

Q: Who are the key vendors in the Global Hereditary Angioedema Treatment Market?

The global hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge. 'CSL Limited', 'Takeda Pharmaceutical Company Limited', 'BioCryst Pharmaceuticals, Inc.', 'Pharming Group N.V.', 'Ionis Pharmaceuticals, Inc.', 'Biogen Inc.', 'Sanofi S.A.', 'Shire plc (acquired by Takeda in 2019)', 'KalVista Pharmaceuticals, Inc.', 'Dyax Corp. (acquired by Shire in 2016)', 'Adverum Biotechnologies, Inc.', 'Amgen Inc.', 'Arrowhead Pharmaceuticals, Inc.', 'BioMarin Pharmaceutical Inc.', 'Catalyst Biosciences, Inc.', 'Attune Pharmaceuticals, Inc.', 'RUCONEST (Pharming Group N.V.)', 'Haegarda (CSL Limited)', 'Firazyr (Shire plc)'

Report ID: SQMIG35J2031 | Region: Global | Published Date: February, 2024
Pages: 157 | Tables: 141 | Figures: 77

Hereditary Angioedema Treatment Market Regional Insights

North America dominated the global hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.

Due to increased patient awareness, Asia-Pacific is expected to dominate the global market. The rest of the world is expected to be a highly profitable in the market during the forecast period, owing to factors such as an increase in the number of reported cases of hereditary angioedema in recent times, increased awareness of rare diseases in developing countries, and the introduction of novel therapies.

Hereditary Angioedema Treatment Market Report Snapshots

License Type Top market research company in USA

File Type

$5,300

BUY NOW GET FREE SAMPLE

Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Hereditary Angioedema Treatment Market size was valued at USD 2.65 billion in 2019 and is poised to grow from USD 2.72 billion in 2023 to USD 10.39 billion by 2031, growing at a CAGR of 2.56% in the forecast period (2024-2031).

The hereditary angioedema treatment market is fragmented, with a prominent market player acquiring a sizable portion. Some of the market's leading companies such as Takeda Pharmaceutical Company Limited, CSL Limited, BIOCRYST PHARMACEUTICALS, INC., Pharming Group N.V., Ionis Pharmaceuticals, Novartis AG, CENTOGENE AG, Sanofi, KalVista Pharmaceuticals, Pfizer Inc., GlaxoSmithKline plc., AstraZeneca, Medtronic are forming multiple strategic alliances in order to increase their market share and get a competitive edge. 'CSL Limited', 'Takeda Pharmaceutical Company Limited', 'BioCryst Pharmaceuticals, Inc.', 'Pharming Group N.V.', 'Ionis Pharmaceuticals, Inc.', 'Biogen Inc.', 'Sanofi S.A.', 'Shire plc (acquired by Takeda in 2019)', 'KalVista Pharmaceuticals, Inc.', 'Dyax Corp. (acquired by Shire in 2016)', 'Adverum Biotechnologies, Inc.', 'Amgen Inc.', 'Arrowhead Pharmaceuticals, Inc.', 'BioMarin Pharmaceutical Inc.', 'Catalyst Biosciences, Inc.', 'Attune Pharmaceuticals, Inc.', 'RUCONEST (Pharming Group N.V.)', 'Haegarda (CSL Limited)', 'Firazyr (Shire plc)'

Researchers and manufacturers around the world are increasing their focus on advanced therapeutics for the treatment of hereditary angioedema disorders and taking the necessary steps to create or advance therapeutics for the treatment of hereditary angioedema disorders. Several manufacturers have recently filed new medication applications in various counties for C1-esterase Inhibitor, Bradykinin B2 Receptor Antagonist, and Kallikrein Inhibitor treatment of Type I, Type II, and Type III HAE. The increased emphasis on sophisticated treatments and innovative drug applications will increase the availability of hereditary angioedema treatment therapies during the forecast period.

Rising awareness of rare conditions and hereditary angioedema in recent years can be credited to the expansion of the market. The primary factors driving the market include novel therapeutics, pipeline medications, and new product launches such as Takhzyro, a lanadelumab monoclonal antibody for the treatment of prophylactic HAE. The majority of pipeline medications are oral, due to which the oral method of administration is growing as a trend in the market. This approach is more convenient for patients and has fewer adverse effects. Companies are attempting to get into the rare illnesses industry with novel products in the pipeline. Due to the market expiration, these players may enter the hereditary angioedema treatment market.

North America dominated the hereditary angioedema therapy market in 2021 and is expected to continue to do so during the forecast period. The high prevalence of hereditary angioedema, substantially better reported disease ratios, high healthcare expenditure, and availability of speciality HAE products are the primary drivers for the growth of the North American hereditary angioedema treatment market.

Feedback From Our Clients

"We have purchased recently a report from SkyQuest Technology, and we are happy to inform you that this report was so useful and practical for our team. Skyquest Team was very active and our queries were followed up completely.It was amazing. "

- Mr. Ali Zali, Commercial Director, ICIIC Iran.

Hereditary Angioedema Treatment Market Regional Insights

Hereditary Angioedema Treatment Market Report Snapshots

Want to customize this report?

FAQs

What is the market size of Hereditary Angioedema Treatment Market?

Who are the key vendors in the Hereditary Angioedema Treatment Market?

What is the key driver of Hereditary Angioedema Treatment Market?

What is the key market trend for Hereditary Angioedema Treatment Market?

Which region accounted for the largest share in Hereditary Angioedema Treatment Market?

Request Free Customization

Related Reports

Feedback From Our Clients

$5,300